Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Condition: Ovarian Cancer Intervention: Drug: Anlotinib Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials